Presentation is loading. Please wait.

Presentation is loading. Please wait.

The obese-asthma phenotype in children: An exacerbating situation?

Published byNoah Lauritzen Modified over 5 years ago

Similar presentations

Presentation on theme: "The obese-asthma phenotype in children: An exacerbating situation?"— Presentation transcript:

1 The obese-asthma phenotype in children: An exacerbating situation?
Cristina Longo, MSc, Gillian Bartlett, PhD, Tibor Schuster, PhD, Francine M. Ducharme, MSc, MD, Brenda MacGibbon, PhD, Tracie A. Barnett, PhD  Journal of Allergy and Clinical Immunology  Volume 141, Issue 4, Pages e4 (April 2018) DOI: /j.jaci Copyright © Terms and Conditions

2 Journal of Allergy and Clinical Immunology 2018 141, 1239-1249
Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © Terms and Conditions

3 Fig 1 Study population flowchart.
Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © Terms and Conditions

4 Fig 2 Marginal probability of remaining exacerbation-free for obesity after initiation of step 3 maintenance therapy. The MSM estimates the marginal probability of remaining exacerbation-free had all patients been, contrary to fact, obese (red line) or nonobese (blue line) throughout follow-up. Survival curves were generated from the obesity MSM rather than the raw empiric data, which might have been misspecified. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © Terms and Conditions

5 Fig 3 Marginal probability of remaining exacerbation-free after initiation of step 3 asthma maintenance therapy regimens by treatment status. The MSM estimates the marginal probability of remaining exacerbation-free had all patients been, contrary to fact, fully adherent to ICS monotherapy (red line), fully adherent to combination therapy (blue line), or completely nonadherent (gray line) throughout follow-up. Survival curves were generated from the treatment MSM rather than the raw empiric data, which might have been misspecified. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © Terms and Conditions

6 Fig 4 Conditional and marginal HRs for obesity and step 3 maintenance therapies for children with mild-to-moderate asthma, as well as their stratified effects. Average HRs ignore the time-varying effect demonstrated in the conditional model for obesity. Marginal and conditional models were adjusted for age, sex, ethnicity, income, global assessment of severity score, number of exacerbations in previous year, exposure to smoke, asthma-related comorbidities, percent predicted FEV1, and season. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © Terms and Conditions

7 Fig 5 Marginal probability of remaining exacerbation-free for treatment groups by obesity status. The MSM estimates the probability of remaining exacerbation-free had all patients been, contrary to fact, obese and fully nonadherent (no use) to both step 3 maintenance therapies (black), nonobese and fully nonadherent (no use) to both step 3 maintenance therapies (gray), obese and fully adherent to ICS monotherapy (bright red), nonobese and fully adherent to ICS monotherapy (dark red), obese and fully adherent to combination therapy (bright blue), and nonobese and fully adherent to combination therapy (dark blue). Survival curves were generated from the obesity-by-treatment joint MSM, rather than the raw empiric data, which might have been misspecified. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © Terms and Conditions

8 Fig E1 Scaled Schoenfeld residual versus time plots with bootstrapped intervals (blue dotted lines) demonstrating the time-varying nature of the HR for obesity in the conditional (A) and marginal (B) Cox model. Bootstrap aggregation or bagging (blue line) averages the HRs over the bootstrap samples as a means of reducing variance arising from within-subject correlation, a feature of the Andersen-Gill formulation of the Cox model. The conditional HR becomes protective at approximately 250 days, whereas the IPCW marginal model corrects for this spurious protective effect. DOS, Depletion of susceptibles. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © Terms and Conditions

Download ppt "The obese-asthma phenotype in children: An exacerbating situation?"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,
The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
What drives prescription patterns in pediatric asthma management?

What drives prescription patterns in pediatric asthma management?
Megan E. Jensen, PhD, Morton J

Megan E. Jensen, PhD, Morton J
Genetic influence on the age at onset of asthma: A twin study

Genetic influence on the age at onset of asthma: A twin study
Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O

Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 
Päivi M. Salo, PhD, Samuel J

Päivi M. Salo, PhD, Samuel J
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation  Rick Admiraal,

Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation  Rick Admiraal,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B
The Finnish experience to save asthma costs by improving care in  

The Finnish experience to save asthma costs by improving care in  
Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012  Anni Nørgaard Jeppesen, MD, Christian Fynbo.

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012  Anni Nørgaard Jeppesen, MD, Christian Fynbo.

Similar presentations

Ads by Google